Aquestive Therapeutics (AQST) Other Non-Current Liabilities (2017 - 2026)

Aquestive Therapeutics' Other Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $6.1 million for Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities rose 172.9% year-over-year to $6.1 million in Q1 2026; TTM through Mar 2026 was $6.1 million, a 172.9% increase from a year earlier, with the FY2025 full-year figure at $7.3 million, up 203.51% from the prior year.
• Other Non-Current Liabilities retreated to $6.1 million in Q1 2026 per AQST's latest filing, from $7.3 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $7.3 million in Q4 2025 and bottomed at $1.9 million in Q1 2022.
• The 5-year median for Other Non-Current Liabilities is $2.1 million (2025), against an average of $2.6 million.
• Across the five-year window, Other Non-Current Liabilities slipped 18.15% in 2022 and soared 203.51% in 2025, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $2.0 million in 2022, then slipped by 0.88% to $2.0 million in 2023, then climbed by 18.8% to $2.4 million in 2024, then surged by 203.51% to $7.3 million in 2025, then slipped by 16.73% to $6.1 million in 2026.
• Per Business Quant, the three latest AQST Other Non-Current Liabilities figures stand at $6.1 million (Q1 2026), $7.3 million (Q4 2025), and $2.1 million (Q3 2025).